Literature DB >> 21250873

Blood coagulation factor Xa as an emerging drug target.

Keren Borensztajn1, C Arnold Spek.   

Abstract

INTRODUCTION: Factor (F)Xa is well-known as an important player in the coagulation cascade responsible for thrombin generation. More recently, FXa emerged as an essential player in cell biology via activation of protease-activated receptors (PAR)-1 and -2. This pleiotropic role of FXa forms the basis for its potential contribution to the pathogenesis of several diseases. AREAS COVERED: The role of FXa in pathophysiology is reviewed with special emphasis on its signal transduction properties. To this end, we first discuss the important role of FXa in the coagulation cascade, we continue with recent data on FXa induced signaling in pathophysiology with special emphasis on tissue remodeling and fibrosis and discuss the potential of FXa as an emerging drug target. EXPERT OPINION: FXa is more than a passive intermediate in the coagulation cascade and FXa may in fact orchestrate fundamental processes during pathophysiology. Targeting FXa may be an exciting new therapeutic strategy in the treatment of (fibro)proliferative diseases for which current treatment options are limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250873     DOI: 10.1517/14728222.2011.553608

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  9 in total

Review 1.  Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.

Authors:  Giovanni Cimmino; Plinio Cirillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 2.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

3.  Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis.

Authors:  Ravi S Keshari; Robert Silasi; Narcis I Popescu; Constantin Georgescu; Hala Chaaban; Cristina Lupu; Owen J T McCarty; Charles T Esmon; Florea Lupu
Journal:  J Thromb Haemost       Date:  2019-10-16       Impact factor: 5.824

Review 4.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

5.  Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.

Authors:  Nicolas Collin; Teresa C F Assumpção; Daniella M Mizurini; Dana C Gilmore; Angélica Dutra-Oliveira; Michalis Kotsyfakis; Anderson Sá-Nunes; Clarissa Teixeira; José M C Ribeiro; Robson Q Monteiro; Jesus G Valenzuela; Ivo M B Francischetti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-12       Impact factor: 8.311

6.  Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.

Authors:  Masanori Tsujimoto; Gen Kuroyanagi; Rie Matsushima-Nishiwaki; Yuko Kito; Yukiko Enomoto; Hiroki Iida; Shinji Ogura; Takanobu Otsuka; Haruhiko Tokuda; Osamu Kozawa; Toru Iwama
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

7.  Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis.

Authors:  Ozlem Gul Utku; Eylem Akbay Karatay; Harun Erdal; Mehmet Arhan; Ibrahim Koral Onal; Mehmet Ibis; Ozgur Ekinci; Canan Yilmaz Demirtas; Selahattin Unal
Journal:  Med Princ Pract       Date:  2015-06-20       Impact factor: 1.927

8.  Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia.

Authors:  Sergi Torramade-Moix; Marta Palomo; Manel Vera; Didac Jerez; Ana Belen Moreno-Castaño; M Urooj Zafar; Jordi Rovira; Fritz Diekmann; Joan Carles Garcia-Pagan; Gines Escolar; Aleix Cases; Maribel Diaz-Ricart
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

Review 9.  New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).

Authors:  Rick H van Gorp; Leon J Schurgers
Journal:  Nutrients       Date:  2015-11-17       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.